fpm/iStock via Getty Images
- Agios Pharmaceuticals (NASDAQ:AGIO) presented positive results from late-stage study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia.
- Stock is down 7% premarket.
- Mitapivat demonstrated a statistically significant reduction in transfusion burden vs placebo
Source link
Related Articles
-
-
-
-
